For people living with psoriasis, effective treatment can dramatically improve quality of life – reducing painful flares, clearing skin, and restoring control. However, many patients face a frustrating barrier: step therapy, also known as “fail first” policies imposed by insurance companies. This system requires patients to try cheaper medications before their insurance will cover the treatments their dermatologist prescribes.
Step therapy isn’t about medical necessity; it’s about cost control. Roughly 40% of psoriasis patients, including 70% of those who have used biologics, have been forced to navigate this process. The consequences include treatment delays, increased disease severity, and unnecessary suffering.
How Step Therapy Works
Insurance companies use a tiered approach: patients must “fail” each step before moving to the next. A typical progression looks like this:
- Topical Treatments: Corticosteroids, vitamin D analogs, and other creams are tried first.
- Phototherapy: Ultraviolet light therapy may be required next.
- Oral Systemics: Older drugs like methotrexate or cyclosporine are often prescribed before biologics.
- Biologics and JAK Inhibitors: These highly effective, but expensive, treatments are only approved after all other options have been exhausted.
This process can take weeks or months, forcing patients to endure prolonged flares while insurers wait for “failure.” Failure isn’t simply a lack of effect: it can also mean intolerable side effects or continued disease progression despite treatment.
The Real-World Impact
Step therapy isn’t just an inconvenience; it has significant consequences:
- Delayed Treatment: A 2025 study found that step therapy delays appropriate treatment by over four months, requiring 1.4 extra appointments and prolonging symptom improvement by roughly 112 days.
- Prolonged Suffering: Patients may experience severe symptoms while waiting for insurance approval. Over half of psoriasis patients report negative mental health impacts from step therapy.
- Administrative Burden: Patients and doctors must spend time documenting treatment failures and filing appeals. Renewals are often required annually, even for effective medications.
The system is inconsistent: rules vary by state, insurer, and even individual plans. Some insurers require multiple failed medications before approving alternatives, while others may allow access after just one attempt.
Navigating the System
Despite the challenges, patients can fight back:
- Understand your policy: Know which medications are covered and what step therapy requirements apply.
- Keep detailed records: Track treatment dates, side effects, and results.
- Work closely with your dermatologist: They can submit prior authorizations, write letters of medical necessity, and file appeals.
- Be proactive: Advocate for yourself, and don’t hesitate to call insurers directly if claims are denied.
- Request exceptions: In some cases, doctors can bypass step therapy if a medication is medically necessary.
The Bigger Picture
Step therapy exists because newer psoriasis treatments – especially biologics and JAK inhibitors – are expensive. Traditional therapies are cheaper, so insurers require patients to try them first. While cost control is the goal, the system often prioritizes profits over patient well-being.
The key takeaway is this: step therapy is a financial barrier that delays effective treatment for psoriasis, forcing patients to endure unnecessary suffering while insurance companies protect their bottom line.
Resources: National Psoriasis Foundation (https://www.psoriasis.org/ ), Step Therapy (https://steptherapy.com/ ).
